PTC Therapeutics, Inc. (PTCT)
63.33
+0.77
(+1.23%)
USD |
NASDAQ |
Oct 09, 10:20
PTC Therapeutics Enterprise Value : 3.680B for Oct. 8, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 08, 2026 | 3.680B |
| October 07, 2026 | 3.736B |
| October 06, 2026 | 3.775B |
| October 05, 2026 | 3.771B |
| October 02, 2026 | 3.755B |
| October 01, 2026 | 3.811B |
| September 30, 2026 | 3.865B |
| September 29, 2026 | 3.880B |
| September 28, 2026 | 3.963B |
| September 25, 2026 | 3.690B |
| September 24, 2026 | 3.657B |
| September 23, 2026 | 3.662B |
| September 22, 2026 | 3.964B |
| September 21, 2026 | 3.905B |
| September 18, 2026 | 3.914B |
| September 17, 2026 | 4.134B |
| September 16, 2026 | 4.099B |
| September 15, 2026 | 3.938B |
| September 14, 2026 | 4.007B |
| September 11, 2026 | 3.972B |
| September 10, 2026 | 4.081B |
| September 09, 2026 | 4.098B |
| September 08, 2026 | 4.201B |
| September 04, 2026 | 4.242B |
| September 03, 2026 | 4.417B |
| Date | Value |
|---|---|
| September 02, 2026 | 4.449B |
| September 01, 2026 | 4.347B |
| August 31, 2026 | 4.262B |
| August 28, 2026 | 4.308B |
| August 27, 2026 | 4.451B |
| August 26, 2026 | 4.524B |
| August 25, 2026 | 4.589B |
| August 24, 2026 | 4.389B |
| August 21, 2026 | 4.285B |
| August 20, 2026 | 4.344B |
| August 19, 2026 | 4.606B |
| August 18, 2026 | 4.519B |
| August 17, 2026 | 4.540B |
| August 14, 2026 | 4.442B |
| August 13, 2026 | 4.464B |
| August 12, 2026 | 4.520B |
| August 11, 2026 | 4.609B |
| August 10, 2026 | 4.686B |
| August 07, 2026 | 4.576B |
| August 06, 2026 | 4.371B |
| August 05, 2026 | 4.234B |
| August 04, 2026 | 4.225B |
| August 03, 2026 | 4.143B |
| July 31, 2026 | 4.134B |
| July 30, 2026 | 4.760B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Biogen, Inc. | 39.33B |
| BioMarin Pharmaceutical, Inc. | 13.97B |
| Arcturus Therapeutics Holdings, Inc. | 197.25M |
| ACADIA Pharmaceuticals, Inc. | 2.488B |
| Alnylam Pharmaceuticals, Inc. | 29.71B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 83.50M |
| Revenue (Quarterly) | 360.52M |
| Total Expenses (Quarterly) | 277.02M |
| EPS Diluted (Quarterly) | 0.9178 |
| Gross Profit Margin (Quarterly) | 91.19% |
| Profit Margin (Quarterly) | 23.16% |
| Earnings Yield | -0.94% |
| Operating Earnings Yield | 2.15% |
| Normalized Earnings Yield | -1.060 |